Contrast-induced nephropathy: Epidemiology and prevention

Minerva Cardioangiologica

Volumn 54, Issue 1, 2006, Pages 109-129

  Bagshaw, S M ^a   Culleton, B F ^b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Contrast media; Coronary artery disease; Kidney diseases

Indexed keywords

ACETYLCYSTEINE; ADENOSINE RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; ANTIBIOTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; FENOLDOPAM; FUROSEMIDE; IOBITRIDOL; IODIXANOL; MANNITOL; NIFEDIPINE; NONIONIC CONTRAST MEDIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E1; THEOPHYLLINE;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS HEMODIAFILTRATION; CONTRAST INDUCED NEPHROPATHY; CRITICAL ILLNESS; DEHYDRATION; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DISEASE COURSE; DIURESIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HEART VENTRICULOGRAPHY; HEMODIALYSIS; HEMOFILTRATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IATROGENIC DISEASE; INTESTINE ISCHEMIA; KIDNEY DISEASE; LENGTH OF STAY; MORTALITY; NEPHROTOXICITY; PATHOPHYSIOLOGY; PROPHYLAXIS; REHYDRATION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; TACHYCARDIA;

ALBERTA; AUSTRALIA; CONTRAST MEDIA; CORONARY ARTERIOSCLEROSIS; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 33644782967     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (183)

1. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243-8.
2. Shusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med 1987;83:65-71.
3. Corwin HL, Teplick RS, Schreiber MJ, Fang LS, Bonventre JV, Coggins CH. Prediction of outcome in acute renal failure. Am J Nephrol 1987;7:8-12.
4. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-6.
5. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-82.
6. Kramer BK, Kammerl M, Schweda F, Schreiber M. A primer in radiocontrast-induced nephropathy. Nephrol Dial Transplant 1999;14:2830-4.
7. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36: 1542-8.
8. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-94.
9. Powe NR, Moore RD, Steinberg EP. Adverse reactions to contrast media: factors that determine the cost of treatment. AJR Am J Roentgenol 1993;161:1089-95.
10. Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with pre-existing renal insufficiency. Am J Cardiol 1999;83:260-3, A5.
11. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism-a critical review. Am J Kidney Dis 1994;24:713-27.
12. Saklayen MG, Gupta S, Suryaprasad A, Azmeh W. Incidence of atheroembolic renal failure after coronary angiography. A prospective study. Angiology 1997;48:609-13.
13. Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. J Am Coll Cardiol 1998;32:1861-5.
14. Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994;5:125-37.
15. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64.
16. Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338-43.
17. Fang LS, Sirota RA, Ebert TH, Lichtenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med 1980;140:531-3.
18. D'Elia JA, Gleason RE, Alday M, Malarick C, Godley K, Warram J et al. Nephrotoxicity from angiographic contrast material. A prospective study. Am J Med 1982;72:719-25.
19. Weinrauch LA, Healy RW, Leland OS Jr, Goldstein HH, Kassissieh SD, Libertino JA et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. Ann Intern Med 1977;86:56-9.
20. Carraro M, Mancini W, Artero M, Stacul F, Grotto M, Cova M et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant 1996;11:444-8.
21. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254-61.
22. Sterner G, Nyman U, Valdes T. Low risk of contrast-medium-induced nephropathy with modern angiographic technique. J Intern Med 2001;250:429-34.
23. Rudnick MR, Goldfarb S. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med 2003;4 Suppl 5:S28-33.
24. Quader MA, Sawmiller C, Sumpio BA. Contrast-induced nephropathy: review of incidence and pathophysiology. Ann Vasc Surg 1998;12:612-20.
25. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin 2005;21:261-80.
26. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
27. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
28. Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195:17-22.
29. Davidson CJ, Hlatky M, Morris KG, Pieper K, Skelton TN, Schwab SJ et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 1989;110:119-24.
30. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990;150: 1237-42.
31. Guitterez NV, Diaz A, Timmis GC, O'Neill WW, Stevens MA, Sandberg KR et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 2002;15:349-54.
32. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86:649-52.
33. Albert SG, Shapiro MJ, Brown WW, Goodgold H, Zuckerman D, Durham R et al. Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Invest Radiol 1994;29:618-23.
34. Moore RD, Steinberg EP, Powe NR, White RI Jr, Brinker JA, Fishman EK et al. Frequency and determinants of adverse reactions induced by high-osmolality contrast media. Radiology 1989;170:727-32.
35. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003;4 Suppl 5:S3-9.
36. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615-20.
37. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15:18-22.
38. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-9.
39. Allgren RL. Update on clinical trials with atrial natriuretic peptide in acute tubular necrosis. Ren Fail 1998;20: 691-5.
40. Lautin EM, Freeman NJ, Schoenfeld AH, Bakal CW, Haramati N, Friedman AC et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol 1991;157:49-58.
41. Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002;223:772-9.
42. Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294-5.
43. Najjar M, Hamad A, Salameh M, Agarwal A, Feinfeld DA. The risk of radiocontrast nephropathy in patients with cirrhosis. Ren Fail 2002;24:11-8.
44. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992;62:413-5.
45. Cohen DJ, Sherman WH, Osserman EF, Appel GB. Acute renal failure in patients with multiple myeloma. Am J Med 1984;76:247-56.
46. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992;183:519-21.
47. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-9.
48. Vlietstra RE, Nunn CM, Narvarte J, Browne KF. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J 1996;132:1049-50.
49. Hemmelgarn BR, Ghali WA, Quan H, Brant R, Norris CM, Taub KJ et al. Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 2001;37:64-72.
50. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;52:409-16.
51. Freeman RV, O'Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068-73.
52. Bagshaw SM, Culleton BF. Acetylcysteine and renal function following coronary angiographic procedures. JAMA 2003;289:2795; author reply 2796.
53. Hoffmann U, Banas B, Fischereder M, Kramer BK. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points. Kidney Blood Press Res 2004;27:161-6.
54. Eisenberg RL, Bank WO, Hedgcock MW. Renal failure after major angiography. Am J Med 1980;68:43-6.
55. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol 1981;136:859-61.
56. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999;33:403-11.
57. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570-4.
58. Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003;93: C29-34.
59. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162: 329-36.
60. Bader BD, Berger ED, Heede M. Fluid administration: when and how much to prevent contrast media nephrotoxicity. J Am Soc Nephrol 2002;11:125A.
61. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-34.
62. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-8.
63. Moore RD, Steinberg EP, Powe NR, Blinker JA, Fishman EK, Graziano S et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992;182:649-55.
64. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-9.
65. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev 1998;3:114-27.
66. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992;41:1008-15.
67. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 1997;272:F292-8.
68. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
69. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
70. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-8.
71. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40: 298-303.
72. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004;25:206-11.
73. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-7.
74. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 2003;64:2182-7.
75. Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004;43:801-8.
76. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004;25:212-8.
77. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-8.
78. MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003;60:458-61.
79. Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol 2004;17:159-65.
80. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003;146:E23.
81. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8.
82. Vallero A, Cesano G, Pozzato M, Garbo R, Minelli M, Quarello F et al. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)]. G Ital Nefrol 2002;19:529-33. Italian.
83. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
84. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336-41.
85. Azmus AD, Gottschall C, Manica A, Manica J, Duro K, Frey M et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol 2005;17:80-4.
86. Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araujo A et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 2005;91: 774-8.
87. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 2004;148: 690-5.
88. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004;44:762-5.
89. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol 2003;58: 555-60.
90. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004; 148: 422-9.
91. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-10.
92. Curhan GC. Prevention of contrast nephropathy. JAMA 2003;289:606-8.
93. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603.
94. Guru V, Fremes SE. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 2004;62:77-83.
95. Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004;117:938-47.
96. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 2004;27:607-10.
97. Liu R, Nair D, Ix J, Moore DH, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 2005;20:193-200.
98. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004;15:761-9.
99. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003;92:1454-8.
100. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after, intravascular angiography: a systematic review and meta-analysis. BMC Med 2004;2:38.
101. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004;65:1366-74.
102. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg 2004;40:1136-41.
103. Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2005;68:2250-5.
104. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy. A case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006;166:161-6.
105. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-42.
106. Canavese C, Petrarulo M, Massarenti P, Berutti S, Fenoglio R, Pauletto D et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 2005;45:540-9.
107. Spielman WS, Arend LJ. Adenosine receptors and signaling in the kidney. Hypertension 1991;17:117-30.
108. Arakawa K, Suzuki H, Naitoh M, Matsumoto A, Hayashi K, Matsuda H et al. Role of adenosine in the renal responses to contrast medium. Kidney Int 1996;49:1199-206.
109. Arend LJ, Bakris GL, Burnett JC Jr, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987;110:406-11.
110. Deray G, Martinez F, Cacoub P, Baumelou B, Baumelou A, Jacobs C. A role for adenosine calcium and ischemia in radiocontrast-induced intrarenal vaso-constriction. Am J Nephrol 1990;10:316-22.
111. Oldroyd SD, Fang L, Haylor JL, Yates MS, El Nahas AM, Morcos SK. Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rat kidney. Clin Sci (Lond) 2000;98:303-11.
112. Gandhi MR, Brown P, Romanowski CA, Morcos SK, Campbell S, el Nahas AM et al. The use of theophylline, an adenosine antagonist in the prevention of contrast media induced nephrotoxicity. Br J Radiol 1992;65:838.
113. Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994;45:1425-31.
114. Erley CM, Heyne N, Burgert K, Langanke J, Risler T, Osswald H. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol 1997;8:1125-32.
115. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002;17:1936-41.
116. Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003;91:1157-62.
117. Shammas NW, Kapalis MJ, Harris M, McKinney D, Coyne EP. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol 2001;13:738-40.
118. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998;11:151-6.
119. Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Muller C et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14:1146-9.
120. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004;19:2747-53.
121. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 2005;165: 1087-93.
122. Schindler R, Stahl C, Venz S, Ludat K, Krause W, Frei U. Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 2001;16:1471-4.
123. Sterner G, Frennby B, Kurkus J, Nyman U. Does postangiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol 2000;34:323-6.
124. Berger ED, Bader BD, Bosker J, Risler T, Erley CM. [Contrast media-induced kidney failure cannot be prevented by hemodialysis]. Dtsch Med Wochenschr 2001;126:162-6. German.
125. Huber W, Jeschke B, Kreymann B, Hennig M, Page M, Salmhofer H et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol 2002;37:471-81.
126. Lehnert T, Keller E, Gondolf K, Schaffner T, Pavenstadt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998;13:358-62.
127. Hsieh YC, Ting CT, Liu TJ, Wang CL, Chen YT, Lee WL. Short- and long-term renal outcomes of immediate prophylactic hemodialysis after cardiovascular catheterizations in patients with severe renal insufficiency. Int J Cardiol 2005;101:407-13.
128. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001;111: 692-8.
129. Younathan CM, Kaude JV, Cook MD, Shaw GS, Peterson JC. Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. AJR Am J Roentgenol 1994;163: 969-71.
130. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-40.
131. Marenzi G, Bartorelli AL. Hemofiltration in the prevention of radiocontrast agent induced nephropathy. Minerva Anestesiol 2004;70:189-91.
132. Tobimatsu M, Konomi K, Saito S, Tsumagari T. Protective effect of prostaglandin E1 on ischemia-induced acute renal failure in dogs. Surgery 1985;98: 45-53.
133. Paller MS, Manivel JC. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 1992;42:1345-54.
134. Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993;44:1217-23.
135. Koch JA, Sketch M, Brinker J, Bernink PJ. [Prostaglandin E1 for prevention of contrast medium-induced kidney dysfunction]. Rofo 1999;170:557-63. German.
136. Sketch MH, Jr., Whelton A, Schollmayer E, Koch JA, Bernink PJ, Woltering F et al. Prevention of contrast media-induced renal dysfunction with prostaglandin El: a randomized, double-blind, placebo-controlled study. Am J Ther 2001;8:155-62.
137. Duan SB, Liu FY, Luo JA, Wu HW, Liu RH, Peng YM et al. Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model. Acta Radiol 2000;41:503-7.
138. Wang YX, Jia YF, Chen KM, Morcos SK. Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001;74:1103-8.
139. Esnault VL. Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists. Nephrol Dial Transplant 2002;17:1362-4.
140. Cacoub P, Deray G, Baumelou A, Jacobs C. No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin Nephrol 1988;29:215-6.
141. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989;4:1030-6.
142. Russo D, Testa A, Delia Volpe L, Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990;55:254-7.
143. Spangberg-Viklund B, Berglund J, Nikonoff T, Nyberg P, Skau T, Larsson R. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol 1996;30:63-8.
144. Khoury Z, Schlicht JR, Como J, Karschner JK, Shapiro AP, Mook WJ et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995;15:59-65.
145. Hall KA, Wong RW, Hunter GC, Camazine BM, Rappaport WA, Smyth SH et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res 1992;53:317-20.
146. Bellomo R, Ronco C. The renal effects of noradrenaline and dopamine. Contrib Nephrol 2001;(132):146-57.
147. Demon MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
148. Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-56.
149. Hans B, Hans SS, Mittal VK, Khan TA, Patel N, Dahn MS. Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency. Radiology 1990;176:651-4.
150. Hans SS, Hans BA, Dhillon R, Dmuchowski C, Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 1998;64:432-6.
151. Weisberg LS, Kurnik PB, Kurnik BR. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail 1993;15:61-8.
152. Kapoor A, Sinha N, Sharma RK, Shrivastava S, Radhakrishnan S, Goel PK et al. Use of dopamine in prevention of contrast induced acute renal failure-a randomised study. Int J Cardiol 1996;53:233-6.
153. Gare M, Haviv YS, Ben-Yehuda A, Rubinger D, Bdolah-Abram T, Fuchs S et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999;34:1682-8.
154. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356: 2139-43.
155. Thompson BT, Cockrill BA. Renal-dose dopamine: a siren song? Lancet 1994;344:7-8.
156. Lee MR. Dopamine and the kidney. Clin Sci (Lond) 1982;62:439-48.
157. Lee MR. Dopamine and the kidney: ten years on. Clin Sci (Lond) 1993;84:357-75.
158. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med 1996;101:49-53.
159. Nichols AJ, Ruffolo RR Jr, Brooks DP. The pharmacology of fenoldopam. Am J Hypertens 1990;3(6 Pt 2):116S-119S.
160. Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann J, McGuire D et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999;27:1832-7.
161. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int 1999;56: 206-10.
162. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
163. Kini AA, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001;2 Suppl 1:519-25.
164. Kini AS, Mitre CA, Kamran M, Suleman J, Kim M, Duffy ME etal. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002;89:999-1002.
165. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002;55:169-73.
166. Madyoon H. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. Rev Cardiovasc Med 2001;2 Suppl 1:S26-30.
167. Madyoon H, Croushore L. Use of fenoldopam for prevention of radiocontrast nephropathy in the cardiac catheterization laboratory: a case series. J Interv Cardiol 2001;14:179-85.
168. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 2001;53:341-5.
169. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290:2284-91.
170. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999;51:521-6.
171. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
172. Kurnik BR, Weisberg LS, Askenase AD, Kurnik PB. Mannitol stimulates atrial natriuretic peptide release in humans. Am J Kidney Dis 1991;17:62-8.
173. Clark BA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis 1997;30:82-6.
174. Rahman SN, Kim GE, Mathew AS, Goldberg CA, Allgren R, Schrier RW et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994;45:1731-8.
175. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997;336:828-34.
176. Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000;36: 767-74.
177. Kurnik BR, Allgren RL, Center FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31:674-80.
178. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 1992;3:58-65.
179. Heyman SN, Clark BA, Cantley L, Spokes K, Rosen S, Brezis M et al. Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol 1993;28:313-8.
180. Oldroyd SD, Haylor JL, Morcos SK. Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology 1995;196: 661-5.
181. Brooks DP, DePalma PD. Blockade of radiocontrast-induced nephrotoxicity by the endothelin receptor antagonist, SB 209670. Nephron 1996;72:629-36.
182. Pollock DM, Polakowski JS, Wegner CD, Opgenorth TJ. Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy. Ren Fail 1997;19:753-61.
183. Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000;57:1675-80.